PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
7.00%
Growth of 7.00% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.
7.88%
Cost growth of 7.88% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
3.45%
Growth of 3.45% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
-3.31%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.45%
Other expenses change of 7.45% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
7.72%
Operating expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 3.23%. Jim Chanos would check for waste.
7.86%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 2.62%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
7.53%
D&A change of 7.53% versus flat Medical - Pharmaceuticals D&A. Walter Schloss would verify adequacy.
-12.68%
EBITDA decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-18.39%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-11.49%
Operating income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-17.27%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-21.34%
Other expenses reduction while Medical - Pharmaceuticals median is -0.66%. Seth Klarman would investigate advantages.
-12.73%
Pre-tax income decline while Medical - Pharmaceuticals median is -0.53%. Seth Klarman would investigate causes.
-18.43%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-106.24%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
44.66%
Income change of 44.66% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
35.20%
Margin change of 35.20% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
44.66%
EPS change of 44.66% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
44.66%
Diluted EPS change of 44.66% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.